These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 22664921)

  • 1. MiRNAs and neural stem cells: a team to treat Parkinson's disease?
    Palm T; Bahnassawy L; Schwamborn J
    RNA Biol; 2012 Jun; 9(6):720-30. PubMed ID: 22664921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tiny non-coding RNAs in Parkinson's disease: implications, expectations and hypes.
    Srivastava G; Dixit A; Prakash O; Singh MP
    Neurochem Int; 2011 Nov; 59(6):759-69. PubMed ID: 21807045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can Parkinson's disease pathology be propagated from one neuron to another?
    Dunning CJ; Reyes JF; Steiner JA; Brundin P
    Prog Neurobiol; 2012 May; 97(2):205-19. PubMed ID: 22115849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MicroRNAs in Parkinson's disease.
    Mouradian MM
    Neurobiol Dis; 2012 May; 46(2):279-84. PubMed ID: 22245218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Embryonic stem cell-derived neuron models of Parkinson's disease exhibit delayed neuronal death.
    Yamashita H; Nakamura T; Takahashi T; Nagano Y; Hiji M; Hirabayashi T; Amano T; Yagi T; Sakai N; Kohriyama T; Matsumoto M
    J Neurochem; 2006 Jul; 98(1):45-56. PubMed ID: 16805795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. microRNAs in Parkinson's Disease: From Pathogenesis to Novel Diagnostic and Therapeutic Approaches.
    Leggio L; Vivarelli S; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Marchetti B; Iraci N
    Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29236052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neural stem cells in Parkinson's disease: a role for neurogenesis defects in onset and progression.
    Le Grand JN; Gonzalez-Cano L; Pavlou MA; Schwamborn JC
    Cell Mol Life Sci; 2015 Feb; 72(4):773-97. PubMed ID: 25403878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
    Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
    Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of Parkinson's disease linked to pathological alpha-synuclein: new targets for drug discovery.
    Lee VM; Trojanowski JQ
    Neuron; 2006 Oct; 52(1):33-8. PubMed ID: 17015225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New therapeutic approaches to Parkinson's disease including neural transplants.
    Kuan WL; Barker RA
    Neurorehabil Neural Repair; 2005 Sep; 19(3):155-81. PubMed ID: 16093408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Viral vectors, animal models and new therapies for Parkinson's disease.
    Schneider B; Zufferey R; Aebischer P
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S169-71. PubMed ID: 18585946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. α-Synuclein synaptic pathology and its implications in the development of novel therapeutic approaches to cure Parkinson's disease.
    Bellucci A; Navarria L; Zaltieri M; Missale C; Spano P
    Brain Res; 2012 Jan; 1432():95-113. PubMed ID: 22153624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new perspective in Parkinson's disease, chaperone-mediated autophagy.
    Li B; Zhang Y; Yuan Y; Chen N
    Parkinsonism Relat Disord; 2011 May; 17(4):231-5. PubMed ID: 21215675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pluripotent stem cells as new drugs? The example of Parkinson's disease.
    Preynat-Seauve O; Burkhard PR; Villard J; Zingg W; Ginovart N; Feki A; Dubois-Dauphin M; Hurst SA; Mauron A; Jaconi M; Krause KH
    Int J Pharm; 2009 Nov; 381(2):113-21. PubMed ID: 19782880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alpha-synuclein in colonic submucosa in early untreated Parkinson's disease.
    Shannon KM; Keshavarzian A; Mutlu E; Dodiya HB; Daian D; Jaglin JA; Kordower JH
    Mov Disord; 2012 May; 27(6):709-15. PubMed ID: 21766334
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-based therapies for Parkinson's disease.
    Dyson SC; Barker RA
    Expert Rev Neurother; 2011 Jun; 11(6):831-44. PubMed ID: 21651331
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Olfactory mucosa is a potential source for autologous stem cell therapy for Parkinson's disease.
    Murrell W; Wetzig A; Donnellan M; Féron F; Burne T; Meedeniya A; Kesby J; Bianco J; Perry C; Silburn P; Mackay-Sim A
    Stem Cells; 2008 Aug; 26(8):2183-92. PubMed ID: 18535154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Over-expression of alpha-synuclein in human neural progenitors leads to specific changes in fate and differentiation.
    Schneider BL; Seehus CR; Capowski EE; Aebischer P; Zhang SC; Svendsen CN
    Hum Mol Genet; 2007 Mar; 16(6):651-66. PubMed ID: 17309880
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Beyond α-synuclein transfer: pathology propagation in Parkinson's disease.
    Hansen C; Li JY
    Trends Mol Med; 2012 May; 18(5):248-55. PubMed ID: 22503115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Midbrain-derived neural stem cells: from basic science to therapeutic approaches.
    Storch A; Sabolek M; Milosevic J; Schwarz SC; Schwarz J
    Cell Tissue Res; 2004 Oct; 318(1):15-22. PubMed ID: 15503150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.